WHAT IS MYEOFIBROSIS?

Myelofibrosis is a condition in which the bone marrow (the spongy tissue inside your bones that helps form blood cells) is gradually replaced by fibrous, scar-like tissue that prevents the marrow from making blood cells normally. This means your body may not be making enough of the cells that fight infection (white blood cells), carry oxygen (red blood cells), and help your blood clot (platelets). Not having enough of these cells can result in anaemia (which can leave you feeling weak or tired), susceptible to infections, or bleeding. Your body may start making blood cells in organs such as your spleen and liver which become bigger as a result. Myelofibrosis occurs when cells that make blood cells inside the bone marrow (stem cells) develop a mutation (change) in the genetic material (DNA).

WHAT IS IMG-7289?

IMG-7289, is a new oral (taken by mouth) medication taken once a day that limits the growth of cells that drive myelofibrosis. IMG-7289 has been studied in patients with other diseases of the bone marrow. This is the first study using IMG-7289 for the treatment of myelofibrosis.

WHAT IS THE DESIGN OF THE IMG-7289-CTP-102 STUDY?

- The IMG-7289-CTP-102 study is an ongoing Phase 2 study in patients with high or intermediate-2 risk Myelofibrosis. To enter this study, participants must have a diagnosis of Post-polycythaemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythaemia Myelofibrosis (PET-MF) or Primary Myelofibrosis (PMF). Participants need to visit a study site to see if they meet the criteria for the study. Treatment with IMG-7289 lasts for 24 weeks. Participants will visit the clinic about 15 times during treatment; weekly for the first 8 weeks, every 2 weeks for the next 8 weeks and then every month for the last 8 weeks. There will be regular physical examinations and laboratory tests such as blood counts. In addition, there will be abdominal imaging (an MRI, or CT, as applicable) to measure spleen volume before dosing and at Weeks 12 and 24, and a bone marrow sample before dosing and at Week 24.
- If participants are receiving clinical benefit from treatment with IMG-7289 at the end of 24 weeks, treatment can continue.

WHERE IS THE STUDY BEING CONDUCTED?

This study is being conducted in the United Kingdom, United States, and in various countries in Europe. For additional information about the study, visit ClinicalTrials.gov and enter identifier (NCT number): NCT03136185.

Thank you for reading this information.

Each participant who enrolls has a meaningful impact on research in this devastating disease and our ability to develop future drug treatments.